Open AccessSorafenib-induced pancreatitis
Author(s) -
Talat Ayyıldız,
Taner Aydın,
Ahmet Tarık Eminler,
Yıldırım Çınar,
Kader İrak,
Murat Kıyıcı,
Ekrem Gürel,
Selim Giray Nak,
Macit Gülten,
Enver Dolar
Publication year - 2015
Publication title -
dergipark (istanbul university)
Language(s) - English
DOI - 10.5835/jecm.omu.32.03.008
Subject(s) - sorafenib , pancreatitis , medicine , cardiology , pharmacology , hepatocellular carcinoma
Sorafenib is an inhibitor of multikinase proteins which is used for metastatic renal cell carcinoma and advanced stage hepatocellular carcinoma. Its side effects include serum amylase and lipase elevations anticipated to occur within first weeks of treatment but clinically and radiologically evident acute pancreatitis develops rarely. Five cases of acute pancreatitis have been reported in literature until date. The case we described here is the sixth case of clinically diagnosed acute pancreatitis.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom